LeonaBio Inc（LONA）财务数据LONALeonaBio Inc

Evaluating the bottom line, LeonaBio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -431.39%, provide a clear picture of how effectively LONA converts its operational activities into shareholder value.

In the context of the broader market, LONA competes directly with industry leaders such as IMA and MREO. With a market capitalization of $41.64M, it holds a significant position in the sector. When comparing efficiency, LONA's gross margin of N/A stands against IMA's N/A and MREO's N/A. Such benchmarking helps identify whether LeonaBio Inc is trading at a premium or discount relative to its financial performance.

LeonaBio has been struggling financially, with a net income loss of $32,948,000 in Q1 2026 and a gross profit of -$231,000. The company has shown consistent losses over the past quarters, indicating a challenging financial situation.